Bolt Biotherapeutics competitors

Zippia score 3.8

Competitor Summary. See how Bolt Biotherapeutics compares to its main competitors:

Xencor has the most employees (156).
The oldest company is Xencor, founded in 1997.

Work at Bolt Biotherapeutics?

Share your experience

Bolt Biotherapeutics vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Bolt Biotherapeutics	2015	3.8	Redwood City, CA	1	$7.7M	91
Eureka Therapeutics	2006	3.8	Emeryville, CA	1	$500,000	50
Immune-Onc Therapeutics	2016	3.6	Palo Alto, CA	1	$440,000	17
Trillium Therapeutics	2004	4.0	-	1	$148,000	20
Immunophotonics	2012	3.7	Columbia, MO	1	$460,000	9
WindMIL Therapeutics	2015	3.7	Baltimore, MD	1	$530,000	30
Xencor	1997	4.5	Monrovia, CA	2	$110.5M	156
Bioniz Therapeutics	2009	3.7	Irvine, CA	1	$1.2M	30

Rate how well Bolt Biotherapeutics differentiates itself from its competitors.

Bolt Biotherapeutics salaries vs competitors

Compare Bolt Biotherapeutics salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Bolt Biotherapeutics	$49,071	$23.59	-

Compare Bolt Biotherapeutics job title salaries vs competitors

Company	Highest salary	Hourly salary
Bolt Biotherapeutics	$33,804	$16.25
Xencor	$38,880	$18.69
Eureka Therapeutics	$34,743	$16.70
Trillium Therapeutics	$33,520	$16.12
WindMIL Therapeutics	$32,230	$15.50
Immunophotonics	$32,142	$15.45
Bioniz Therapeutics	$32,066	$15.42
Immune-Onc Therapeutics	$32,045	$15.41

Do you work at Bolt Biotherapeutics?

Is Bolt Biotherapeutics able to compete effectively with similar companies?

Bolt Biotherapeutics jobs

Bolt Biotherapeutics revenue vs competitors

Bolt Biotherapeutics revenue is $7.7M. Among it's competitors, the company with the highest revenue is Xencor, $110.5M . The company with the lowest revenue is Trillium Therapeutics, $148.0K.

Bolt Biotherapeutics and similar companies CEOs

CEOBio

Lu Alleruzzo

Immunophotonics

Immunophotonics Inc. is a biotech company developing drugs to improve outcomes of common interventional oncology procedures, such as tumor ablation and ablative radiation therapy (e.g. SBRT).Our lead compound, a polymer (IP-001), is designed to be injected intratumorally immediately after a standard interventional procedure, which in turn may induce a polyclonal T cell response against the cancer.For more information: www.immunophotonics.com[email protected]

Jan Skvarka

Trillium Therapeutics

Jan Skvarka is a Board Member at TRILLIUM THERAPEUTICS INC and President/CEO at TRILLIUM THERAPEUTICS INC and is based in Cambridge, Massachusetts. He has worked as President/CEO at Tal Medical Inc, Partner at Bain & Company, and Manager at Pricewaterhouse Coopers (PwC). Jan attended Harvard Business School between 1998 and 1999 and University of Economics, Bratislava, Slovakia.